Alternative RNA splicing plays a key role in regulating gene function and influencing protein expression diversity. In the present study, an AC-33 transcript variant (NCBI Reference Sequence: NM_001308229.1), splice variant (sv)AC3-33, was successfully cloned from the MCF-7 breast cancer cell line by reverse transcription PCR using primers based on expressed sequence tags. The aim of the present study was to investigate the structure and function of svAC3-33. svAC3-33 has an open reading frame of 1,825 base pairs, lacks AC3-33 exon 2 and is encoded by 294 amino acids. svAC3-33 is localized within the cytoplasm. The Cell Counting Kit-8 and EdU detection of cell proliferation assays showed that svAC3-33 inhibited MCF-7 cell proliferation. Similarly, svAC3-33 knockdown by RNA interference was shown to have the opposite effect by repressing the cell cycle progression of breast cancer cells. Furthermore, the data indicated that svAC3-33 may upregulate the expression of p21. The present study provides evidence that the increased expression of svAC3-33 may inhibit the activity of the transcription factor AP-1. The luciferase reporter gene assay detected a downregulation of the expression of c-Jun, but not c-Fos, which in turn affected cell proliferation. In conclusion, these results indicated a function for svAC3-33 in inhibiting the cell proliferation of MCF-7 cells by regulating the AP-1 signaling pathway.
Introduction
Based on high-throughput screening techniques, a novel human gene, chromosome 3 open reading frame 33 (AC3-33), capable of inhibiting phorbol 12-myristate 13-acetate and AP-1 activation, has been identified from 650 known human genes (1) . Previously, it was demonstrated that the AC3-33 gene is widely expressed in the adrenal gland and cervix (2) . Further studies on AC3-33 indicate that it is a secretory protein that inhibits ETS transcription factor ELK1 transcriptional activity through the ERK1/2 pathway (2, 3) . Alternative RNA splicing not only increases the diversity of mRNA expression, but also plays an important role in the regulation of gene function (4, 5) . Wang et al (6) found that a single-block intronic expressed sequence tag (EST) containing a polyadenylation site could form a 3'exon site, thus forming transcript variants. Although one AC3-33 transcript variant has previously been reported (1) , previous data suggested that other AC3-33 isoforms may exist.
Breast cancer is the most common cancer in women worldwide, and its incidence is increasing, making breast cancer a major public health problem (7) . Numerous signaling pathways can modulate the development of breast cancer cells, which can affect the cell cycle as well as processes involving the activation and inhibition of specific genes. The activation and inhibition of the transcription factor AP-1 can greatly affect the growth and reproduction of cancer cells, regulating the development of many deadly cancer types (7, 8) . AP-1 is mainly composed of the c-Jun, c-Fos, MAF and activating transcription factor protein families. In human cells, AP-1 comprises c-Jun and c-Fos, which can activate and affect numerous signaling pathways, in addition to regulating cell growth and reproduction (9) (10) (11) (12) (13) (14) (15) . Previous studies have demonstrated that infection, growth factors and cancer cells affect the expression of AP-1-related signaling pathway, leading to the division, differentiation and apoptosis of cancer cells (16) (17) (18) (19) .
In the present study, a second AC3-33 transcript variant was successfully cloned, splice variant (sv)AC3-33. The data
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also characterized svAC3-33 and demonstrated the subcellular localization of the encoded protein. Furthermore, the effect of raised svAC3-33 expression on cell proliferation was demonstrated. Our present evidence shows that svAC3-33 may inhibit MCF-7 cell progression by downregulating c-Jun, which is an important member of the AP-1 signaling pathway. Plasmid construction. A possible novel AC3-33 isoform was identified in the University of California Santa Cruz Genome Browser sequence database (http://genome.ucsc. edu/cgi-bin/hgGateway). svAC3-33 and full-length (or wild-type) AC3-33 are two alternatively spliced transcripts of the AC3-33 gene containing different open reading frames (ORFs). The full-length fragment of svAC3-33 cDNA was obtained by RT-PCR from MCF-7 cells using the following primers: Forward 5'-TAT AAG CTT ATG GCG GGG CAG CCC GCG-3' and reverse 5'-TAT GGA TCC CAC CCT TTT CTA CGA AAG TTT-3'. BamHI and HindIII recognition sites were added to the primers. The purified PCR product was recombined with p-enhanced green fluorescent protein (EGFP)-C3 vector (BD Biosciences) to form a recombinant expression vector. To construct pEGFP-C3-svAC3-33, the corresponding primers were used for fusion with the N-terminal GFP tag in the PEGFP-C3 vector with BamHI and HindIII. All clones were confirmed by sequencing using an ABI Prism 3100 Genetic Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.). After confirmation, all plasmids were extracted and purified for transfection using EndoFree Plasmid Maxi Kit (Qiagen, USA). Signal IP 4.0 Server (http://www.cbs.dtu. dk/services/SignalP) was used to analyze the signal peptide of the svAC3-33 protein; TMHMM server v 2.0 (http://www. cbs.dtu.dk/services/TMHMM-2.0/) was used to predict the transmembrane location of proteins.
Materials and methods

PCR
Preparation of the small interfering (si)RNA. The siRNA sequence for the svAC3-33 gene was designed and synthesized. This siRNA sequence was located in the ORF of the svAC3-33 gene, and the target sequence of the siRNA was 5'-GGA CGA UUA CGC CGA AUAA-3'. A nonsense sequence siRNA was used as a control, named si-NC. Sense and antisense strands were designed and synthesized by Beijing Genomics Institute. According to the manufacturer's instructions (pSilencer 4.1-CMV neo siRNA Expression Vector kit), strands were annealed to the corresponding sites of pSilencer 4.1-CMVneo (Thermo Fisher Scientific, Inc.; www.ambion. com/techlib/msds) HindIII and BamHI, thus constructing a silent plasmid, named si-svAC3-33.
Cell culture and transient transfection. MCF-7 cells were supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin in DMEM (Gibco; Thermo Fisher Scientific, Inc.), and maintained at 37˚C with 5% CO 2 . Then 2x10 4 , 5x10 4 and 1.2x10 4 MCF-7 cells were seeded into six-well, 24-well or 96-well plates, respectively, and transiently transfected with pEGFP-C3, pEGFP-C3-svAC3-33, si-NC or si-svAC3-33 plasmids using and Lipofectamine ® 2000 (all, Thermo Fisher Scientific, Inc.) was used according to the manufacturer's protocol.
Subcellular localization. pEGFP-C3 and pEGFP-C3-svAC3-33 plasmids were transiently transfected into MCF-7 cells in a 6-well plate, and then each well of the cells were washed twice with PBS. After transfection MCF-7 cells were incubated at 37˚C for 24 h, then 4% paraformaldehyde was used to fix MCF-7 cells for 30 min at room temperature, and DAPI was added to stain the nuclei for 2 min at room temperature. After washing twice with PBS, images of MCF-7 cells were captured (magnification x400; IX71 inverted fluorescence microscope; Olympus Corporation) and analyzed using ImageJ (version 1.40; National Institutes of Health).
Cell Counting Kit-8 (CCK-8) assay. pEGF P-C3, pEGFP-C3-svAC3-33, si-NC or si-svAC3-33 plasmids were transiently transfected into MCF-7 cells as previously described. After transfection MCF-7 cells were incubated at 37˚C for 24 h, 2,000 cells were seeded into 96-well plate. CCK-8 solution (10 µl; Beijing Zoman Biotechnology Co., Ltd.) was added to each well, and the cells were incubated at 37˚C, 5% CO 2 for 2 h according to the manufacturers protocol. The absorbance at 450 nm was measured daily with a microplate reader for 5 days.
EdU cell proliferation assay. MCF-7 cells were transiently transfected with pEGFP-C3, pEGFP-C3-svAC3-33, si-NC or si-svAC3-33 plasmids in 96-well plates at 50-60% confluence of 5x10 4 . The steps of cell incubation and staining were based on the manufacturer's instructions. MCF-7 cells were fixed using 4% paraformaldehyde for 30 min at room temperature, washed with 0.5% Triton X-100 three times, and images were captured using an IX71 inverted fluorescence microscope (magnification, x200, IX71 inverted fluorescence microscope; Olympus Corporation).
Dual-luciferase assay to measure AP-1 activity. MCF-7 cells were co-transfected with pEGFP-C3 or pEGFP-C3-svAC3-33; si-NC (nonsense siRNA) or si-svAC3-33 and pAP-1-Luc plasmid and pGL3-Basic plasmid which contain the Renilla luciferase gene to normalize the transfection efficiency (all, Promega Corporation). After transfection the MCF-7 cells were incubated for 24 h at 37˚C, and cells were lysed and assayed. Luciferase activities were tested using the Dual-Luciferase ® Reporter Assay System (Promega Corporation) following the manufacturer's instructions and measured using a microplate luminometer reader (Tecan Group, Ltd.). Three independent repeat tests were performed.
Western blot analysis. MCF-7 cells were transfected with si-NC or si-svAC3-33, pEGFP-C3 or pEGFP-C3-svAC3-33, and MCF-7 cells were incubated at 37˚C for 48 h, then total cell extracts and the western blotting was performed as previously described (20) . The total protein concentration was determined using the BCA protein assay kit (Sangon Biotech Co., Ltd.). Specific antibodies for the following proteins were used: Anti-green fluorescent protein (1: RNA extraction and reverse transcription-quantitative PCR (RT-qPCR). TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract the total RNA from MCF-7 cells. M-MLV reverse transcriptase (Promega Corporation) was used for RT-PCR, and the first strand cDNA was synthesized (9) . Primers were designed and synthesized by Beijing Genomics Institute, and the primers were as follows: p15, forward 5'-CTA GTG GAG AAG GTG CGA CA-3' and reverse 5'-ACC AGC GTG TCC AGG AAG-3'; p21, forward 5'-CCC GTG AGC GAT GGA ACT-3' and reverse 5'-AGG CAC AAG GGT ACA AGA CA-3'; p27 forward 5'-TAG AGG GCA AGT ACG ACG AGT GG-3' and reverse 5'-CAG GTC GCT TCC TTA TTC C-3'; p53 forward 5'-CCT CCT CAG CAT CTT ATC CG-3' and reverse 5'-CAC AAA CAC GCA CCT CAAA-3' GAPDH, forward 5'-AAA GGG TCA TCA TCT CTG-3' and reverse 5'-GCT GTT GTC ATA CTT CTC-3'. qPCR was performed with the designed primers. The reaction was carried out using a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific, Inc.). GAPDH-80 was used as the internal control. Amplification was performed under the following conditions: 1 min at 95˚C; 5 sec at 95˚C; 30 sec at 60˚C for 40 cycles; Melt Curve 65 to 95˚C. Gene expression levels were calculated as a ratio of the expression of GAPDH, and data were analyzed using the 2 -ΔΔCt method (21) .
Statistical analysis. All of the data were collected from three independent experiments. Statistical analyses were carried out using one-way ANOVAs followed by post hoc Tukey tests, or Student's t-tests. P<0.05 was considered to indicate a statistically significant difference.
Results
Cloning and characterization of the svAC3-33 transcript variant. The novel human gene AC3-33 is a secretory protein, and can suppress the activity of the transcription factor AP-1 (1). In the present study, specific primers were used based on an EST from AC3-33, to clone a novel splice variant of AC3-33 cDNA [the PCR product is ~1,825 base pairs (Fig. 1A) ] from MCF-7 cells, which was designated svAC3-33. Only svAC3-33 was amplified, and no expression of AC3-33 was noted (Fig. 1A) . Therefore, the effects of this siRNA on cell proliferation were due to the silencing of the svAC3-33 transcript (Fig. 3A) . Full-length AC3-33 and svAC3-33 transcripts are the alternatively spliced transcripts of the AC3-33 gene, which contains different ORFs (Fig. 1B) . The putative svAC3-33 protein contains 294 amino acids (Fig. 1C) and has a predicted molecular mass of 29 kDa. Signal IP 4.0 Server analysis revealed that the svAC3-33 contained no signal peptides, whereas TMHMM server v. 2.0 analysis revealed that the svAC3-33 protein does not contain a transmembrane spanning region. The C3orf33 gene is located on human chromosome 3q25.31. According to the NCBI database (NM_173657.2 and NM_001308229.1 https://www.ncbi.nlm.nih.gov/nuccore/NM_001308229.2/), svAC3-33 comprises five exons and four introns. svAC3-33 is very similar to AC3-33, except that it lacks exon 2 entirely and has a pre-translation initiation site, resulting in the coding sequence starting earlier than AC3-33 (Fig. 1C ).
There are currently no studies indicating the function of svAC3-33'.
Subcellular localization of svAC3-33.
A pEGFP-C3-svAC3-33 plasmid was constructed and transiently transfected it into MCF-7 cells. svAC3-33 was mainly located in the cytoplasm ( Fig. 2A ) and the size of the pEGFP-C3-svAC3-33 encoded protein was around 56 k Da (Fig. 2B ).
svAC3-33 expression inhibits cell proliferation.
Western blotting indicated that svAC3-33 was expressed in MCF-7 cells following transfection (Fig. 2B) . MCF-7 cells were co-transfected with pEGFP-C3-svAC3-33 and si-NC, pEGFP-C3-svAC3-33 and si-svAC3-33 for 48 h. pEGFP-C3-svAC3-33 expression was qualitatively observed to be inhibited by si-svAC3-33 at the protein level (Fig. 3A) .
Counting of cell numbers with ССK-8 indicated that the expression of svAC3-33 inhibited the proliferation of MCF-7 cells compared with those of the negative control group. Similarly, inhibiting endogenous svAC3-33 expression with siRNA may reduce the proliferation of MCF-7 cells (Fig. 3B ). EdU+ cell numbers in svAC3-33-expressing cells decreased significantly after 2 days, compared with those of cells transfected with the empty vector (Fig. 3C ). The EdU cell proliferation assay revealed a marked decrease in the number of MCF-7 cells in the S phase following transfection with pEGFP-C3-svAC3-33 (Fig. 3C) . The EdU assay indicated that the percentage of cells in the S phase decreased from 30.27% in the transfection with control cells to 23.96%
in pEGFP-C3-svAC3-33 cells at 48 h following transfection. treating pEGFP-C3-svAC3-33+ cells with si-svAC3-33, compared with si-NC treated cells, increased the percentage of cells in the S phase from 25.37 to 40.21% at 48 h (Fig. 3D) . Taken together, these data suggested that svAC3-33 may inhibit the cell cycle progression of MCF-7 cells from the S phase.
To investigate the relationship between svAC3-33 and cell proliferation, the impact of svAC3-33 on the mRNA expression of p15, p21, p27, p53 and proliferation-related genes was examined. It was found that svAC3-33 only regulates p21 expression ( Fig. 3E-F) . Compared with the pEGFP-C3 transfected negative control group, the expression of p21 mRNA in the svAC3-33+ group was significantly higher than that in the control group. After silencing svAC3-33 with si-svAC3-33, compared with the si-NC negative control group, the mRNA expression levels of p21 were downregulated by 60% at 48 h (Fig. 3G) .
Effects of svAC3-33 on AP-1 signaling. The role of the AP-1 signaling pathways in the antiproliferative function of svAC3-33 was subsequently examined. The dual-luciferase reporter assay was used to investigate the function of svAC3-33. Increased expression of svAC3-33 inhibited the activity of AP-1 compared with the transfection with empty vector controls in MCF-7 cells. Compared with the transfection with the si-NC-treated control, svAC3-33 knockdown by RNA interference increased the activity of AP-1 (Fig. 4A ). c-Jun and c-Fos are the two important components of the transcription factor AP-1. Western blot analysis was used to determine which components of the specific transcription factor mediated the process wherein svAC3-33 suppressed the AP-1 activity (Fig. 4B) . The expression levels of c-Jun protein were reduced by the increased expression of svAC3-33 (Fig. 4C) , whereas there was no significantly change in the protein expression levels of c-Fos (Fig. 4D) . These data demonstrate that svAC3-33 knockdown by RNA interference caused the upregulation of c-Jun, but not c-Fos. 
Discussion
Breast cancer is one of the deadliest cancer types worldwide. Breast cancer results from cell cycle disorganization that leads to uncontrolled cellular pro liferation (7) . Several studies have reported that in breast cancer, the expression levels of various growth factors are altered, which contributes to tumor progression and proliferation. Studies have shown that AP-1 plays a critical role in mediating the proliferation of breast cancer cells. It is estimated that 40-60% of human genes have alternatives vs. Alternative RNA splicing is able to modulate the functions of genes by increasing the number of transcripts, and therefore the number of proteins, that come from a single gene (22) (23) (24) (25) . The process of alternative splicing is regulated by a number of splicing factors, whose expression and activity are tightly regulated during development, cell cycle progression and cell differentiation. Previous studies have demonstrated that intron removal from a pre-mRNA by RNA splicing was initially thought to be controlled by intron splicing signals (22, 26) , the regulation of alternative splicing is closely related to the function of cells. Alternative RNA splicing is mainly mediated and executed by exonic splicing enhancers as well as suppressors or silencers (27, 28) . p21 is an important member of the family of cyclin-dependent kinase inhibitors. It is closely related to tumor inhibition and can coordinate the relationship between the cell cycle, and DNA replication and repair, thus closely linking tumor suppression with the cell cycle. Under cellular stress conditions, p53 positively modulates p21. In turn, p21 exerts an inhibitory effect on cell-dependent kinases, thereby preventing cell cycle progression through the detection of DNA damage. It has been reported that the overexpression of estrogen receptor α in MCF-7 cells not only directly suppresses the activity of the p21 promoter, but also reduces the expression of p21 at both the mRNA and protein levels (29) . It has been reported that the sustained arrest on the cell cycle caused by raised p21 expression could only be achieved when p53 was present in the cell and capable of transcriptionally activating the cyclin dependent kinase inhibitor 1A or p21 (30) . Downregulating certain cyclins and upregulating of p21 and p27 at the transcript level may promote cell cycle arrest, and in turn promote growth inhibition (31) .
Many studies have shown that p21 is a potent regulator of cell proliferation in different cell cultures. For example, in NIH3T3 cells, the hepatitis C virus (HCV) core protein inhibits the transcription of p21 by the transforming growth factor (TGF)-β response element on the p21 promoter, indicating that the HCV core protein inhibits transcription by the inhibition of the TGF-β pathway, thereby promoting cell cycle progression (32) . c-Jun, a member of the transcription factor AP-1 family, is a key inducer of hepatocyte proliferation, which regulates liver regeneration by inhibiting p21 activity (33) . These results are consistent with the present findings that svAC3-33 may contribute to the upregulation of p21 at the mRNA level in MCF-7 breast cancer cells. transfected with pEGFP-C3 or pEGFP-C3-svAC3-33 for 24 h and the expression of p15, p21, p27 and p53 was evaluated by RT-qPCR. However, no significant differences were found of p15, p27 and p53 compared with pEGFP-C3 group (P>0.05). (F) MCF-7 cells were transfected with pEGFP-C3 or pEGFP-C3-svAC3-33 for 24 h. The expression of p21 at the mRNA level was measured at different time points (0, 24, and 48 h) after transfection, using RT-qPCR. GAPDH was used to normalize the p21 level. (G) si-svAC3-33 was transfected into MCF-7 cells. Control MCF-7 cells were treated with a scrambled siRNA. The efficiency of svAC3-33 mRNA knockdown was examined by RT-semiquantitative PCR. Compared with the si-NC control group, svAC3-33 was downregulated after transfection of si-svAC3-33 group. The inhibition of p21 mRNA level was determined at different time points (0, 24 and 48 h) after transfection, using RT-qPCR. GAPDH was used to normalize the p21 level, and then values were further normalized against the corresponding 0 h levels. Data were collected from three independent experiments. * P<0.05 vs. respective control. EGFP, enhanced green fluorescent protein; RT, reverse transcription; q, quantitative; siRNA, small interfering RNA; si-NC, nonsense siRNA; si-svAC3-33, siRNA targeting svAC3-33; sv, splice variant.
In this present study, a novel splice variant of AC3-33 was successfully cloned, designated svAC3-33. Notably, svAC3-33 and AC3-33 have different structures but have the same subcellular localization; they are both predominantly expressed in the cytoplasm (2) . In the present study, the contribution of svAC3-33 to the regulation of MCF-7 cell proliferation was identified. The present study also examined the effect of svAC3-33 on the transcriptional activity of AP-1. It was demonstrated in this present study that increasing the expression of svAC3-33 caused the inhibition of AP-1. This also promoted the translocation of AP-1 into the nucleus and the binding of AP-1 with DNA in MCF-7 cells. A Previous study indicated that the transcriptional activity of AP-1 is mainly mediated by c-Jun, and c-Fos (34) . Additionally, this present study identified that svAC3-33 exerted its functional role through the c-Jun signaling pathway, but not through c-Fos. It would be valuable to investigate and elucidate the further mechanisms of action that svAC3-33 functions through.
In conclusion, a novel splice variant of AC3-33 was successfully cloned, designated svAC3-33, which has a different structure and expression profile than AC3-33. Notably, svAC3-33 was predominantly expressed in the cytoplasm. Moreover, svAC3-33 inhibits MCF-7 cell cycle progression and the transcription of the AP-1 reporter gene by downregulating the expression of c-Jun, but not c-Fos, inhibiting MCF-7 cell proliferation.
